These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 30350431

  • 21. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E, Dreger P.
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [Abstract] [Full Text] [Related]

  • 22. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam CS, Stilgenbauer S.
    Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
    [Abstract] [Full Text] [Related]

  • 23. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H, Pfeifer D, Ihorst G, Pantic M, Wehrle J, Rüter BH, Bullinger L, Hackanson B, Germing U, Kuendgen A, Platzbecker U, Döhner K, Ganser A, Hagemeijer A, Wijermans PW, Döhner H, Duyster J, Lübbert M.
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
    Chapiro E, Lesty C, Gabillaud C, Durot E, Bouzy S, Armand M, Le Garff-Tavernier M, Bougacha N, Struski S, Bidet A, Laharanne E, Barin C, Veronese L, Prié N, Eclache V, Gaillard B, Michaux L, Lefebvre C, Gaillard JB, Terré C, Penther D, Bastard C, Nadal N, Fert-Ferrer S, Auger N, Godon C, Sutton L, Tournilhac O, Susin SA, Nguyen-Khac F, GroupeFrancophone de Cytogénétique Hématologique(GFCH) and the French Innovative Leukemia Organization (FILO) group.
    Am J Hematol; 2018 Mar; 93(3):375-382. PubMed ID: 29194741
    [Abstract] [Full Text] [Related]

  • 27. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
    Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T, European Research Initiative on CLL (ERIC).
    Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
    [Abstract] [Full Text] [Related]

  • 28. Development of locus specific sub-clone separation by fluorescence in situ hybridization in suspension in chronic lymphocytic leukemia.
    Do CH, Bailey S, Macardle C, Thurgood LA, Lower KM, Kuss BJ.
    Cytometry A; 2017 Nov; 91(11):1088-1095. PubMed ID: 29024486
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E, Norberg M, Kanduri M, Tobin G, Säisänen L, Aberg M, Gustafsson MG, Sundström C, Rosenquist R, Aleskog A.
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
    Griffin R, Wiedmeier-Nutor JE, Parikh SA, McCabe CE, O'Brien DR, Boddicker NJ, Kleinstern G, Rabe KG, Bruins L, Brown S, Bonolo de Campos C, Ding W, Leis JF, Hampel PJ, Call TG, Van Dyke DL, Kay NE, Cerhan JR, Yan H, Slager SL, Braggio E.
    Blood Adv; 2023 Jul 11; 7(13):3169-3179. PubMed ID: 36877634
    [Abstract] [Full Text] [Related]

  • 33. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
    Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC.
    Nat Commun; 2017 Jul 28; 8(1):153. PubMed ID: 28751718
    [Abstract] [Full Text] [Related]

  • 34. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
    Malcikova J, Pavlova S, Kozubik KS, Pospisilova S.
    Hum Mutat; 2014 Jun 28; 35(6):663-71. PubMed ID: 24415659
    [Abstract] [Full Text] [Related]

  • 35. Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
    Nguyen-Khac F, Baron M, Guièze R, Feugier P, Fayault A, Raynaud S, Troussard X, Droin N, Damm F, Smagghe L, Susin S, Leblond V, Dartigeas C, Van den Neste E, Leprêtre S, Bernard OA, Roos-Weil D, on behalf the FILO (French Innovative Leukaemia Organization) Group.
    Br J Haematol; 2024 Aug 28; 205(2):495-502. PubMed ID: 38654616
    [Abstract] [Full Text] [Related]

  • 36. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG.
    Lancet Oncol; 2016 Jun 28; 17(6):768-778. PubMed ID: 27178240
    [Abstract] [Full Text] [Related]

  • 37. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Chin-Yee B, Sadikovic B, Chin-Yee IH.
    Br J Haematol; 2020 Mar 28; 188(5):652-660. PubMed ID: 30836431
    [Abstract] [Full Text] [Related]

  • 38. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
    Puiggros A, Venturas M, Salido M, Blanco G, Fernandez-Rodriguez C, Collado R, Valiente A, Ruiz-Xivillé N, Carrió A, Ortuño FJ, Luño E, Calasanz MJ, Ardanaz MT, Piñán MÁ, Talavera E, González MT, Ortega M, Marugán I, Ferrer A, Gimeno E, Bellosillo B, Delgado J, Hernández JÁ, Hernández-Rivas JM, Espinet B, Grupo Cooperativo Español de Citogenética Hematológica (GCECGH), Grupo Español de Leucemia Linfática Crónica (GELLC).
    Genes Chromosomes Cancer; 2014 Sep 28; 53(9):788-97. PubMed ID: 24915757
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
    Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwänen C, Döhner H, Stilgenbauer S.
    Blood; 2008 Oct 15; 112(8):3322-9. PubMed ID: 18689542
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.